Core Viewpoint - Enwei Pharmaceutical, established in 2005 and listed in 2022, specializes in the pharmaceutical sector with a focus on gynecology, pediatrics, and respiratory medications, holding a notable brand presence in China [1] Financial Performance - For Q3 2025, Enwei Pharmaceutical reported revenue of 637 million yuan, ranking 51st among 69 companies in the industry, with the industry leader, Baiyunshan, generating 61.606 billion yuan [2] - The company's net profit for the same period was 36.5847 million yuan, placing it 46th in the industry, while the top performer, Yunnan Baiyao, reported a net profit of 4.789 billion yuan [2] Financial Ratios - As of Q3 2025, Enwei Pharmaceutical's debt-to-asset ratio was 27.60%, lower than the industry average of 32.81% [3] - The company's gross profit margin stood at 48.22%, which is below the industry average of 52.44% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 13.72% to 6,340, while the average number of shares held per shareholder increased by 261.71% to 16,200 [5]

Core Viewpoint - Enwei Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 36.76% but a recent decline in the last 20 and 60 days, indicating potential volatility in the market [1]. Company Overview - Enwei Pharmaceutical, established on May 19, 2005, and listed on September 21, 2022, is located in Chengdu, Sichuan Province. The company focuses on the research, production, and sales of traditional Chinese medicine and chemical drugs, particularly in gynecology, pediatrics, and respiratory medications [1]. - The revenue composition of Enwei Pharmaceutical is as follows: gynecology products 46.21%, other products 31.74%, cold medications 14.71%, pediatrics 6.90%, and others 0.44% [1]. Financial Performance - For the first half of 2025, Enwei Pharmaceutical reported a revenue of 449 million yuan, representing a year-on-year growth of 15.73%. The net profit attributable to the parent company was 38.34 million yuan, showing a significant increase of 113.80% [1]. - Since its A-share listing, Enwei Pharmaceutical has distributed a total of 185 million yuan in dividends [2]. Shareholder Information - As of June 30, 2025, the number of shareholders for Enwei Pharmaceutical was 7,348, a decrease of 13.66% from the previous period. The average number of circulating shares per shareholder increased by 21.82% to 4,478 shares [1]. - Among the top ten circulating shareholders, Rongtong Health Industry Flexible Allocation Mixed A/B (000727) is the second-largest shareholder with 529,400 shares, a decrease of 47.06% from the previous period. Rongtong Xin New Growth Mixed A (011403) and Rongtong Value Growth Mixed A (015553) have exited the top ten list [2].

Core Insights - Enwei Pharmaceutical's stock decreased by 0.48% on October 10, with a trading volume of 37.23 million yuan [1] - The company reported a financing net buy of -1.97 million yuan on the same day, indicating more repayments than new purchases [1] - As of October 10, the total margin balance for Enwei Pharmaceutical was 98.07 million yuan, accounting for 3.05% of its market capitalization [1] Financial Performance - For the first half of 2025, Enwei Pharmaceutical achieved a revenue of 449 million yuan, representing a year-on-year growth of 15.73% [2] - The net profit attributable to the parent company for the same period was 38.34 million yuan, showing a significant increase of 113.80% year-on-year [2] Shareholder Information - As of June 30, 2025, the number of shareholders for Enwei Pharmaceutical was 7,348, a decrease of 13.66% from the previous period [2] - The average number of circulating shares per shareholder increased by 21.82% to 4,478 shares [2] - The company has distributed a total of 185 million yuan in dividends since its A-share listing [3] Institutional Holdings - As of June 30, 2025, the second-largest circulating shareholder was Rongtong Health Industry Flexible Allocation Mixed A/B, holding 529,400 shares, which is a decrease of 470,600 shares from the previous period [3] - Rongtong Xin New Growth Mixed A and Rongtong Value Growth Mixed A have exited the list of the top ten circulating shareholders [3]